During this discussion, Jeffrey D. Dunn, PharmD, MBA, explains how the rapid development of specialty drugs for the treatment of castration-resistant prostate cancer (CRPC) has increased the amount of pharmacoeconomic spending in the United States.
Because there are several options available, and because clinicians have different treatment preferences, Michael Kolodziej, MD, discusses why it is necessary to determine a proper sequencing plan before administering treatment.
Raoul S. Concepcion, MD, agrees that drug sequencing is a major challenge. However, he believes that because so many treatment options are available, clinicians need to individualize therapy when treating patients with CRPC.
Dr Dunn, Dr Concepcion, and David Quinn, MD, review the costs of new agents and discuss why it is important for insurers to provide coverage toward research that tests drug sequencing.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More